This may be related to the markedly different tumor collections (advanced stage versus early stage BCs, enrichment for lobular carcinomas) differences in assays used or the introduction of IPH-926 and human placenta tissue as a benchmark to define high BCAR4 expression. This evidence concerns the gene BCAR4 and breast lobular carcinoma.